| Oct 24 |
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
|
| Oct 22 |
Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for
|
| Oct 18 |
CHMP maintains negative opinion on PTC Therapeutics' DMD treatment
|
| Oct 18 |
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
|
| Oct 18 |
CHMP Maintains Negative Opinion on Translarna™ Reexamination
|
| Oct 17 |
Will PTC Therapeutics (PTCT) Report Negative Q3 Earnings? What You Should Know
|
| Oct 14 |
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
|
| Oct 9 |
PTC Therapeutics Inc (PTCT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Oct 9 |
PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?
|
| Oct 9 |
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
|
